The effect of proton pump inhibitors (PPI) on dacomitinib (DACO) pharmacokinetics and efficacy in non-small cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutation

Abstract

an indolent progress. In addition, although osimertinib showed good control of BM, local therapy although show be taken into consideration for patients with BM. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest. 124P The effect of proton pump inhibitors (PPI) on dacomitinib (DACO)pharmacokinetics and efficacy in non-small cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutation